drugset / Trial / NCT00115635
Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The aim of the study is to determine the optimal dose of the combination of docetaxel and gemcitabine in patients with hormone refractory prostate cancer, and evaluate this dose with respect to efficacy and toxicity in a phase II trial.
Timeline
- Start
- 2005-03
- Primary completion
- —
- Completion
- 2007-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |